In conclusion, we provided a systematic and comprehensive analysis of CCRCC and is the first to suggest that ITGAX, LAPTM5, and SERPINE1 might be used as biomarkers for the new clinical diagnosis and treatment of CCRCC. This evidence concerns the gene LAPTM5 and nonpapillary renal cell carcinoma.